Take Action On PFAS To Protect Your Critical Processes

By James Hathcock, Principal Director, Regulatory and Validation Strategy, Quality and Regulatory Affairs, Cytiva

As awareness grows around the health risks associated with per- and polyfluoroalkyl substances (PFAS), regulatory pressure is mounting. While a full ban may be on the horizon, the lack of viable alternatives in many industries presents a complex challenge. PFAS materials play a critical role in numerous applications, and removing them without a suitable replacement could disrupt essential processes—particularly in sectors like pharmaceutical manufacturing. Policymakers are expected to weigh these concerns carefully, and socio-economic impact assessments will likely support exemptions for industries where PFAS use remains indispensable.

Understanding where these substances are most critical—and where innovation is urgently needed—will be key to navigating the transition ahead.